ZLAB
Zai Lab Limited · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -14.3% ·
share flow -21.4% ·
net new positions -16.7%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 40 | -10 | 13.04M | $247.56M | +1 | −11 |
| Q1 2026 | 51 | -8 | 9.02M | $169.34M | +7 | −15 |
| Q4 2025 | 58 | 0 | 14.32M | $252.66M | +1 | −1 |
| Q3 2025 | 13 | -2 | 15.41M | $522.27M | — | −2 |
| Q2 2025 | 12 | -2 | 15.57M | $544.48M | — | −2 |
| Q1 2025 | 12 | 0 | 13.16M | $475.75M | — | — |
| Q4 2024 | 12 | 0 | 16.81M | $440.22M | +1 | −1 |
| Q3 2024 | 11 | +1 | 20.32M | $490.64M | +1 | — |
| Q2 2024 | 10 | — | 17.23M | $298.54M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 6.20M | — | $216.72M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Fidelity (FMR) ✦ | 6.20M | — | $216.72M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Fidelity (FMR) ✦ | 6.20M | — | $216.72M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Fidelity (FMR) ✦ | 6.20M | — | $216.72M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Fidelity (FMR) ✦ | 6.20M | — | $216.72M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Fidelity (FMR) ✦ | 6.20M | — | $216.72M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Capital World Investors ✦ | 6.04M | +0.5% | $211.09M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 8 | Wellington Management ✦ | 1.38M | -62.2% | $48.15M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 9 | Wellington Management ✦ | 1.38M | -62.2% | $48.15M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | Wellington Management ✦ | 1.38M | -62.2% | $48.15M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 11 | Wellington Management ✦ | 1.38M | -62.2% | $48.15M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | Wellington Management ✦ | 1.38M | -62.2% | $48.15M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Wellington Management ✦ | 1.38M | -62.2% | $48.15M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 14 | Wellington Management ✦ | 1.38M | -62.2% | $48.15M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 15 | Wellington Management ✦ | 1.38M | -62.2% | $48.15M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | Wellington Management ✦ | 1.38M | -62.2% | $48.15M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 17 | BlackRock ✦ (passive) | 455.29K | — | $15.92M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | BlackRock ✦ (passive) | 455.29K | — | $15.92M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | BlackRock ✦ (passive) | 455.29K | — | $15.92M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Citadel Advisors ✦ | 366.21K | -4.2% | $12.81M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 21 | Citadel Advisors ✦ | 366.21K | -4.2% | $12.81M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 22 | D. E. Shaw & Co. ✦ | 279.66K | -9.2% | $9.78M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 23 | Point72 Asset Management ✦ | 252.40K | +186.3% | $8.83M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 24 | Renaissance Technologies ✦ | 232.90K | +175.6% | $8.14M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 25 | T. Rowe Price ✦ | 153.04K | -93.2% | $5.35M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 26 | State Street Global Advisors ✦ (passive) | 138.72K | +0.8% | $4.85M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 27 | Geode Capital Management ✦ (passive) | 56.52K | -3.4% | $1.98M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 28 | Marshall Wace ✦ | 24.46K | -12.4% | $855,226 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 29 | Marshall Wace ✦ | 24.46K | -12.4% | $855,226 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Millennium Management | $3.51M | was 0.0% |
| Two Sigma Investments | $2.02M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 97 holders, 28.24M shares, $515.77M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 260 sh · $7,020
Director · 8.51K sh · $212,650
Officer · 619 sh · $15,475
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology